Are doctors really happy in 2025? Host Andrew uncovers the tough realities behind physician well-being—why burnout is rising, why most doctors would trade pay for time, and what actually makes happiness possible in medicine. Hear candid voices from the front lines and discover why a growing number of doctors are rethinking what matters most.

Join Mike on Curie as we explore the future of medicine in 2050. From AI-driven diagnostics and immersive medical education to precision genomics and telemedicine, this episode uncovers how emerging technologies will reshape healthcare delivery in the U.S. We also discuss ethical challenges and the vital role of physicians in an AI-augmented world. A must-listen for healthcare professionals curious about the next frontier in medicine.

In this investigative episode, Mike explores the complex reasons behind America’s poor health outcomes despite leading the world in healthcare spending. From ultra-processed foods and insulin resistance to chronic inflammation and the promise of new weight-loss drugs, we unravel the biology, environment, and policy factors driving obesity and chronic disease in the U.S. A must-listen for healthcare professionals seeking a deep dive into the nation’s health crisis.

In this investigative episode, Mike dives deep into the unprecedented decision by Health Secretary Robert F. Kennedy Jr. to abruptly fire the entire CDC Advisory Committee on Immunization Practices (ACIP). Exploring the implications for public health, trust in vaccines, and healthcare policy, we examine the controversial backgrounds of new appointees and the urgent reactions from the medical community. What does this political shakeup mean for vaccination rates, patient care, and the future of science-based healthcare in America?

We survey healthcare professionals constantly—on treatments, on tech, on trends. But how often is that research actually used to shape decisions? And what do clinicians really think about being surveyed in the first place?

In this episode, we unpack the role of HCP market research in today’s healthcare economy. Why it’s done, how it’s evolving, and whether it still holds real value. Featuring insights from industry insiders and critical reflections on how pharma and MedTech listen—or don’t—to the voices of frontline care.

In this episode of Curie, we dive into the early but extraordinary results from two CAR-T cell therapy trials that are rewriting what’s possible for glioblastoma—a brain cancer with a devastating prognosis. Andrew takes you through new data from Mass General and the University of Pennsylvania, where some patients have not just responded, but are alive and well nearly two years after treatment.

With quotes from top researchers like Dr. Bryan Choi and Dr. Stephen Bagley, we explore how this groundbreaking treatment works, why a few patients are experiencing durable remissions, and what hurdles remain before CAR-T can become a viable option for more people with this lethal disease.

Is glioblastoma finally meeting its match? Tune in to find out.

In this extended wrap-up from ASCO 2025, Mike breaks down four defining themes from the meeting: AI’s leap from buzzword to bedside, NIH funding threats that could shake innovation, China’s rising role in global oncology R&D, and five paradigm-shifting clinical trials with the potential to reshape patient care. Featuring insights from ASCO leadership, Google, and frontline HCPs from the ZoomRx panel, this is your all-in-one debrief on the most important takeaways from the year’s biggest oncology conference.

Trump’s drug pricing executive order might sound bold—but what’s behind the rhetoric? In this episode of Curie, host Andrew sits down with Dr. David Introcaso, healthcare policy expert and host of The Healthcare Policy Podcast, to unpack the legal, economic, and political minefield that surrounds America’s $5 trillion healthcare system.

From Medicare price negotiations to pharma's pushback, Dr. Introcaso offers a sharp, no-nonsense take on what’s at stake, what’s realistic, and why this moment might signal a deeper reckoning with how the U.S. approaches cost, coverage, and care.

This is a must-listen conversation for any healthcare professional trying to make sense of drug pricing headlines—and what they mean for clinical practice.